Short Interest in GoodRx Holdings, Inc. (NASDAQ:GDRX) Increases By 6.6%

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 7,930,000 shares, a growth of 6.6% from the November 30th total of 7,440,000 shares. Approximately 9.1% of the shares of the company are sold short. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is presently 5.9 days.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently made changes to their positions in the company. ClariVest Asset Management LLC raised its stake in GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock valued at $1,527,000 after purchasing an additional 42,097 shares during the period. American Century Companies Inc. acquired a new position in GoodRx during the second quarter valued at $18,183,000. Cornercap Investment Counsel Inc. lifted its stake in GoodRx by 1.7% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after acquiring an additional 1,266 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in GoodRx during the 2nd quarter worth about $43,000. Finally, XTX Topco Ltd grew its stake in GoodRx by 42.4% during the 2nd quarter. XTX Topco Ltd now owns 29,560 shares of the company’s stock valued at $231,000 after acquiring an additional 8,801 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on GDRX shares. Barclays decreased their target price on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Citigroup lowered their price objective on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Mizuho started coverage on GoodRx in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Finally, Morgan Stanley dropped their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $8.37.

GoodRx Stock Performance

Shares of GDRX opened at $4.65 on Thursday. The company has a 50-day moving average of $5.01 and a two-hundred day moving average of $6.75. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -155.00, a PEG ratio of 3.54 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx has a one year low of $4.09 and a one year high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.